SLC25A47: A promising drug target for hepatocellular carcinoma and its potential as a biomarker

Target Name: SLC25A47

NCBI ID: G283600

SLC25A47

SLC25A47: A promising drug target for hepatocellular carcinoma and its potential as a biomarker

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with the majority of cases arising from hepatitis B or C virus infections. The development of HCC is a complex process that involves multiple factors, including liver damage, genetic mutations, and environmental factors. One of the underlying mechanisms that contribute to the development and progression of HCC is the dysfunction of the mitochondria, which are the primary energy producers in the body. Therefore, targeting the regulation of mitochondrial function is a promising strategy for the treatment of HCC.

SLC25A47: A protein of interest

SLC25A47 is a protein that is expressed in the liver and other tissues, and it is known to be a hepatocellular carcinoma (HCC) downregulated mitochondrial carrier protein. Mammalian HCC is a heterogeneous disease, and different subtypes of HCC have different expression patterns of SLC25A47. However, studies have shown that SLC25A47 is overexpressed in HCC tissues and is associated with poor prognosis in patients with advanced HCC.

SLC25A47 functions as a mitochondrial carrier protein, which plays a crucial role in the delivery of nutrients and oxygen to the mitochondria. Mammalian HCC is characterized by the dysfunction of the mitochondria, which leads to energy metabolism disorders and increased oxygen demand. The dysfunction of the mitochondria can result in the production of reactive oxygen species (ROS), which can cause damage to tissues and contribute to the development of HCC.

SLC25A47 is a key regulator of mitochondrial function in HCC. It has been shown to be involved in the regulation of mitochondrial fusion, which is critical for the production of ATP, the energy currency of the cell. SLC25A47 has been shown to promote mitochondrial fusion by interacting with the protein p276 (also known as PDCD1) and the protein Apc120, which are involved in the regulation of mitochondrial fusion and the expression of SLC25A47.

SLC25A47 also plays a role in the regulation of mitochondrial import, which is the process by which mitochondrial proteins are transported into the mitochondria. Studies have shown that SLC25A47 is involved in the regulation of mitochondrial import by interacting with the protein T-tubulin, which is a key regulator of mitochondrial transport.

SLC25A47 as a drug target

The dysfunction of the mitochondria in HCC is a known therapeutic target, and targeting SLC25A47 as a drug target could be a promising strategy for the treatment of HCC. Several studies have shown that inhibiting SLC25A47 can significantly reduce the development of HCC in animal models of HCC.

One of the potential mechanisms by which SLC25A47 could be targeted as a drug is its role in the regulation of mitochondrial function. By inhibiting SLC25A47, it is possible to disrupt the regulation of mitochondrial function, which could lead to the production of ROS and the development of HCC.

Another potential mechanism by which SLC25A47 could be targeted as a drug is its role in the regulation of cell signaling pathways. SLC25A47 has been shown to be involved in several signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth, angiogenesis, and survival. By inhibiting SLC25A47

Protein Name: Solute Carrier Family 25 Member 47

Functions: Uncoupling protein which may catalyze the physiological 'proton leak' in liver. Overexpression induces the dissipation of mitochondrial membrane potential

The "SLC25A47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets